---
schema_version: "secwatch.filing_event.v1"
accession: "0001785530-25-000030"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:40:40.841375+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Werewolf Therapeutics Q3 net loss $16.4M, cash $65.7M; key trial updates due Q4 2025

## Summary
- Cash and equivalents $65.7M as of Sept 30, 2025, expected to fund operations into Q4 2026.
- Net loss of $16.4M for Q3 2025, comparable to $16.7M in Q3 2024; R&D expense $11.6M, G&A $4.1M.
- WTX-124 received Fast Track Designation; interim Phase 1/1b data and End of Phase 1 FDA meeting expected in Q4 2025.
- WTX-330 Phase 1b/2 update and development plan expected in Q4 2025.
- WTX-1011 (anti-STEAP1 T-cell engager) in IND-enabling studies; target candidate nomination planned by year-end.

## SEC filing metadata
- accession: 0001785530-25-000030
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000178553025000030/0001785530-25-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000178553025000030/howl-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001785530-25-000030
- JSON: https://secwatch.observer/filing/0001785530-25-000030.json
- Plain text: https://secwatch.observer/filing/0001785530-25-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.